Human papillomavirus (HPV) is a very common virus spread through intimate skin-to-skin contact, including sexual contact. It is the most common sexually transmitted infection, and nearly all sexually active people get at least one type at some point. Most infections clear on their own, but some persist and can lead to cancer or genital warts.

It is a preventive vaccine that protects against the HPV types most likely to cause cancer and genital warts, by preparing your immune system before exposure so those infections cannot take hold.

The main vaccines are Gardasil 9 (9-strain), the older Gardasil (4-strain), and Cervavac. In the US, Gardasil 9 is the only one currently used. India's national programme uses Gardasil-4 (quadrivalent).

HPV can cause cervical, vaginal, vulvar, penile, and anal cancers, plus cancers of the back of the throat (oropharyngeal). Vaccination has been shown to prevent about 90% of these HPV-attributable cancers.

Yes — the 4-strain vaccine covers HPV types 6 and 11, which cause about 90% of genital warts.

It uses virus-like particles (VLPs) — empty shells that mimic the outer surface of the real virus but contain none of its genetic material. The immune system recognizes these shells as foreign and makes antibodies. If you later encounter real HPV, those antibodies neutralize it before it can cause infection.

HPV's outer shell is built mainly from a protein called L1. Produced on its own, L1 spontaneously self-assembles into a hollow particle shaped like the virus's shell, with no viral DNA inside. It looks like HPV to the immune system and is very good at triggering a strong antibody response, which is why it forms the basis of the vaccine.

No. It is a recombinant (lab-produced) vaccine made of empty protein shells grown in yeast cells — no live, weakened, or whole virus and no viral DNA. Because there is no genetic material, it cannot infect you or cause HPV-related disease.

Yes. Gardasil and Gardasil 9 use an aluminium-salt adjuvant, a long-used ingredient that strengthens and lengthens the immune response.

The vaccine prevents new infections but does not treat existing ones, so the antibodies need to be in place before exposure. That is why it is routinely recommended in early adolescence.

The original Gardasil (quadrivalent) protected against HPV types 6, 11, 16, and 18. Gardasil 9 (nonavalent) covers those four plus five more high-risk types: 31, 33, 45, 52, and 58.

To catch more cancer-causing types. Types 16 and 18 cause about 70% of cervical cancers, and types 31, 33, 45, 52, and 58 cause roughly another 10–20%. This raises coverage from about 70% to about 90% of cervical cancers.

Types 6 and 11 are low-risk and cause most genital warts; types 16 and 18 are the main high-risk cancer types; and types 31, 33, 45, 52, and 58 are additional high-risk cancer types covered only by the 9-strain vaccine.

Yes — they all use the same L1 virus-like-particle technology; the main difference is how many HPV types each includes.

On each VLP, hundreds of L1 proteins are packed in a dense, repeating array, sending an exceptionally strong activation signal to the immune system's B cells. That produces long-lived antibody-making cells and durable protection from very few doses, and growing evidence shows a single dose can be highly effective.

Yes. It was approved in 2006 after extensive testing and trials, and its safety has been continuously monitored ever since. It contains no live or killed virus.

Most are mild and short-lived: pain, redness, or swelling at the injection site, and sometimes headache, fever, or fatigue. Fainting can occur after the shot, so recipients may be asked to sit or lie down for about 15 minutes afterward.

No. There is no evidence the vaccine causes infertility; this is a common myth. By preventing cervical cancer and its treatment, it can actually help protect future fertility.

Yes. The HPV vaccine can be safely co-administered with other routine vaccines.

It is routinely recommended at ages 11–12 and can start as early as age 9. Giving it before likely exposure provides the best protection.

Yes. It protects against penile, anal, and many oral and throat cancers, as well as genital warts, and reduces transmission. Boys and girls alike should be vaccinated.

Gardasil 9 is approved through age 45. For adults aged 27–45, vaccination is based on a shared decision with a healthcare provider, since many adults have already been exposed to some HPV types.

It is not federally required in the US. Requirements vary by country, state, and school system.

Per the FDA-approved Gardasil 9 prescribing information: for people aged 9 through 14, a 2-dose schedule (second dose 6–12 months after the first) OR a 3-dose schedule (0, 2, 6 months). If the second dose is given less than 5 months after the first, a third dose should be added at least 4 months after the second. For people aged 15 through 45, a 3-dose schedule (0, 2, 6 months). This is still the official label even though public-health bodies have moved toward fewer doses.

In January 2026 the CDC moved to recommending a single dose for routine adolescent vaccination, moving away from its previous schedule of 2 doses (ages 9–14) or 3 doses (age 15 and older). Three doses are still advised for people who are immunocompromised, including those with HIV. During the transition, some CDC materials and the manufacturer label still describe the older multi-dose schedule.

In its December 2022 position paper, the WHO endorsed a single-dose schedule as an alternative (off-label) option that gives comparable protection. WHO recommends: a 1- or 2-dose schedule for girls aged 9–14; a 1- or 2-dose schedule for girls and women aged 15–20; and 2 doses (6 months apart) for women older than 21. Immunocompromised people, including those with HIV, should receive at least 2 doses, and 3 where possible.

Note: schedules differ by country and are changing as single-dose evidence grows. Confirm the current schedule with your provider.

Large trials have shown a single dose can be about as protective as two. Public-health bodies (WHO, and now the CDC) have moved to fewer doses to simplify delivery and widen access, while the manufacturer's FDA-approved label changes more slowly and still lists the multi-dose schedules. That is why you may see different numbers from different sources at the same time.

When the WHO first endorsed it in 2022 it was described as an off-label alternative — meaning it wasn't yet written into the manufacturer's approved labelling, even though the evidence supported it. Many national programmes have since adopted single-dose schedules.

More doses are advised: the CDC and manufacturer guidance call for 3 doses, and the WHO recommends at least 2 and ideally 3. This group is also a high priority for vaccination.

Generally no — standard practice is not to restart a series even after long gaps. Whether any further dose is needed is best decided with your provider based on your age and history.

Highly effective. In large trials, the vaccine was at least 97% protective against new infection with the main cancer-causing types, and population studies show it has lowered rates of HPV pre-cancers and cancers.

Protection is long-lasting — studies show it holding up well for more than a decade — and no booster dose is currently recommended.

Yes. The vaccine does not cover every cancer-causing HPV type, so routine cervical screening (Pap and/or HPV tests) remains important.

Low-risk HPV types — mainly 6 and 11 — cause about 90% of genital warts. These types rarely lead to cancer.

No. It only prevents new infections. Existing warts are managed separately, with treatments such as topical medications, freezing, or removal by a clinician.

No. Common skin warts come from different HPV types, are not sexually transmitted, and are not what this vaccine targets — it focuses on the genital and mucosal types.

Rarely. The vaccine covers the types behind about 90% of warts, but not 100%, so other types could occasionally still cause them.

Generally no. The wart-causing types (6 and 11) are low-risk. Cancer is driven mainly by high-risk types such as 16 and 18.

Vaccination is the main tool. Condoms lower the risk but don't eliminate it, since HPV spreads through skin-to-skin contact in areas a condom may not cover. Limiting the number of partners also reduces exposure.

Yes. You may still benefit, because you're unlikely to have been exposed to every type the vaccine covers. It won't clear an existing infection, but it can protect against the other types.

It is not recommended during pregnancy, mainly because data in pregnancy are limited — not because it is known to be harmful. The usual advice is to wait until after the pregnancy.

Yes, and it is recommended for them, with extra doses as noted in the dosing section (3 doses per CDC/manufacturer; at least 2 and ideally 3 per WHO).

In the US it is covered by almost every health insurance plan, usually at no cost to the patient. Uninsured children may get it free through the Vaccines for Children (VFC) program.

At doctors' offices, community health clinics, local health departments, school-based health centres, and often at pharmacies.

Yes. India launched a nationwide HPV Vaccination Programme that provides the vaccine free of cost at designated government health facilities for eligible girls.

Prime Minister Narendra Modi launched it on 28 February 2026 from Ajmer, Rajasthan, with States and Union Territories holding simultaneous launch events the same day.

The programme targets girls aged 14 years — about 1.15 crore girls every year across all States and UTs. Girls who turn 15 within 90 days of the launch are also eligible during the intensive three-month campaign. Vaccination is voluntary and requires parental consent.

A single dose of the Gardasil-4 (quadrivalent) vaccine is given free of cost, in line with the single-dose approach now used in many countries.

No. The free national programme currently targets 14-year-old girls (plus those turning 15 within the campaign window). Boys, younger or older girls, and adults are not covered under this drive and would use private vaccination.

At government facilities: Ayushman Arogya Mandirs, Primary Health Centres (PHCs), Community Health Centres (CHCs), Sub-District and District Hospitals, and Government Medical Colleges and Hospitals.

Registration and appointment booking are done through U-WIN, the government's national immunisation platform (formerly Co-WIN). You can use the U-WIN web portal at uwin.mohfw.gov.in or the "U-WIN Citizen" mobile app (Google Play / App Store).

Log in with your mobile number and the OTP you receive; choose member type (for example, parent/guardian adding a child); enter the girl's details; search for the nearest vaccination centre by district, sub-district, or PIN code; and book an appointment. Automated SMS alerts confirm registration and the dose given.

Yes. A digital certificate can be downloaded from U-WIN, with hard copies available on request. During the campaign, the left index finger is marked after vaccination.

There is an intensive 90-day (three-month) drive conducted daily for maximum coverage; afterwards the vaccine continues to be available on routine immunisation days.

You can register and book a slot in advance on U-WIN, but vaccination is also delivered through school and facility sessions during the campaign. Checking locally at your nearest government health centre is the easiest way to confirm timing.

It is run by the Ministry of Health & Family Welfare and is supported by partners including Gavi, the Vaccine Alliance, and the WHO.

The single-dose approach reflects strong evidence that one dose offers comparable protection, which makes a national programme simpler and more affordable to deliver at scale. The 4-strain vaccine covers types 6, 11, 16, and 18 — including 16 and 18, which cause the large majority of cervical cancers in India.

Cervavac is India's first indigenously developed HPV vaccine, made by the Serum Institute of India with the Department of Biotechnology and launched in 2022. It is a quadrivalent vaccine — it protects against HPV types 6, 11, 16, and 18, the same four types as the original Gardasil (Gardasil-4), and it uses the same virus-like-particle technology as the imported vaccines. The main differences are coverage and cost: Cervavac and Gardasil-4 cover four types, while Gardasil 9 covers nine (those four plus 31, 33, 45, 52, and 58); Cervavac is much cheaper because it is made in India.

Both protect against types 16 and 18, which cause the large majority of cervical cancers, and both also cover types 6 and 11 (genital warts). The real trade-off is broader coverage versus cost. Gardasil 9 adds five more high-risk types, while Cervavac costs a small fraction of the price — roughly ₹2,000 MRP per dose for Cervavac versus about ₹9,000–11,000 per dose for Gardasil 9. There is no single right answer; it depends on your budget and how much you value the extra strains, and it is best decided with your doctor.

For the four types it covers, yes. Cervavac was approved after Phase 2/3 clinical trials and produced a strong immune response — antibody levels reported to be around a thousand times higher than baseline against all four targeted types. The difference between Cervavac and Gardasil 9 is not effectiveness against the shared types, but breadth: Gardasil 9 protects against five additional cancer-causing types that Cervavac does not include.

You are well protected against the most important types, but not as broadly. Types 16 and 18 — covered by both vaccines — cause about 80–85% of cervical cancers in India, and Gardasil 9's five extra types account for roughly another 10–15%. So Cervavac leaves a modest gap that Gardasil 9 closes. Whether that gap is worth the extra cost is a personal decision.

This is genuinely a judgement call. Because types 16 and 18 alone drive about 80–85% of cervical cancers in India, and Cervavac covers both (plus the wart-causing types 6 and 11), it delivers most of the benefit at a fraction of the cost. Gardasil 9 buys incremental protection from the five additional types. For someone who is cost-sensitive, taking any vaccine — such as Cervavac — is far better than skipping vaccination over price; for someone who can afford it and wants the broadest coverage, Gardasil 9 adds a margin of protection. Both are reasonable choices — the least good option is remaining unvaccinated.

Although Cervavac was developed and launched in India as a 'Made in India' milestone, the national rollout that began in 2026 started with Gardasil (the quadrivalent vaccine from MSD/Merck), with procurement supported by Gavi, the Vaccine Alliance. A major factor was the campaign's move to a single-dose schedule. The choice drew some criticism given the long wait for the indigenous option, but both vaccines cover the same four HPV types.